Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Archive for April, 2010

Autoimmune breakthrough evades resistance issue

Thursday, April 8th, 2010

Although commercially successful, Remicade, Humira, and Enbrel have many limitations due to allergies or infections. Their high immunogenicity, their loss of effectiveness over time, and their expense (typically costing $15,000 to $20,000 per patient per year) make these monoclonal antibodies less than ideal treatments. French biotechnology company, Neovacs SA is ...

   
©2012 UBM Canon